Dr. Rami Komrokji, MD

• Hematology & Oncology

*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.

• Jordan University School Of Medicine

  Medical School, 1996

• English

• Arabic

• Real-world diagnostic testing patterns for assessment of ring sideroblasts andSF3B1mutations in patients with newly diagnosed lower-risk myelodysplastic syndromes, 2020-11-21

• Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome, 2022-11-04

• The National MDS Natural History Study: design of an integrated data and sample biorepository to promote research studies in myelodysplastic syndromes, 2019-05-21

• Genomic Biomarkers to Predict Resistance to Hypomethylating Agents in Patients With Myelodysplastic Syndromes Using Artificial Intelligence, 2019-09-20

• Comparing the prognostic value of risk stratifying models for patients with lower-risk myelodysplastic syndromes: Is one model better?, 2015-08-11

• Prognostic Significance of Serial Molecular Annotation in Myelodysplastic Syndromes (MDS) and Secondary Acute Myeloid Leukemia (sAML), 2020-07-29

• Novel and emerging therapies for the treatment of polycythemia vera, 2014-10-29

• Differential response to hypomethylating agents based on sex: a report on behalf of the MDS Clinical Research Consortium (MDS CRC), 2016-10-24

• Outcomes After Induction Chemotherapy in Patients With Acute Myeloid Leukemia Arising From Myelodysplastic Syndrome, 2010-11-08

• Evolutionary action score identifies a subset ofTP53mutated myelodysplastic syndrome with favorable prognosis, 2021-03-06

• Expansion of Effector Memory Regulatory T-cells Represents A Novel Prognostic Factor in Lower Risk Myelodysplastic Syndrome, 2012-08-08

• Health-Related Quality of Life Outcomes in Patients with Myelodysplastic Syndromes with Ring Sideroblasts Treated with Luspatercept in the MEDALIST Phase 3 Trial, 2021-12-22

• Phase II Randomized Double-Blinded Study of Pracinostat in Combination with Azacitidine in Patients with Untreated Higher-Risk Myelodysplastic Syndromes, 2017-01-17

• Ruxolitinib for Myelofibrosis - An Update of Its Clinical Effects, 2013-10-02

• Integrated Human and Murine Clinical Study Establishes Clinical Efficacy of Ruxolitinib in Chronic Myelomonocytic Leukemia, 2021-07-12

• Validation of International Working Group response criteria in higher-risk myelodysplastic syndromes: A report on behalf of the MDS Clinical Research Consortium, 2020-12-22

• Beyond hypomethylating agents failure in patients with myelodysplastic syndromes, 2014-06-11

• Diagnostic and molecular testing patterns in patients with newly diagnosed acute myeloid leukemia in the Connect®MDS/AML Disease Registry, 2020-06-30

• Prognosis of patients with intermediate risk IPSS-R myelodysplastic syndrome indicates variable outcomes and need for models beyond IPSS-R, 2018-09-26

• A Multi-Institution Phase I Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML), 2016-02-08

• ProspectiveCYP2C19-Guided Voriconazole Prophylaxis in Neutropenic AML Patients Reduces the Incidence of Subtherapeutic Antifungal Plasma Concentrations, 2019-11-01

• Phase I Clinical Trial of Oral Rigosertib in Patients with Myelodysplastic Syndromes, 2013-06-21

• Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms, 2021-06-25

• Subsequent primary malignancies and acute myelogenous leukemia transformation among myelodysplastic syndrome patients treated with or without lenalidomide, 2016-04-20

• Association of EZH2 protein expression by immunohistochemistry in myelodysplasia related neoplasms with mutation status, cytogenetics and clinical outcomes, 2018-01-23

• Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis, 2022-02-26

• The ABNL-MARRO 001 study: a phase 1-2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes, 2022-09-24

• A phase 2 trial of the oral smoothened inhibitor glasdegib in refractory myelodysplastic syndromes (MDS), 2019-03-30

• SF3B1Mutations Negatively Predict for Response to Immunosuppressive Therapy in Myelodysplastic Syndromes, 2020-01-10

• There's Risk, and Then There's RISK: The Latest Clinical Prognostic Risk Stratification Models in Myelodysplastic Syndromes, 2014-07-11

• MYC Overexpression is Associated with an Early Disease Progression from MDS to AML, 2021-10-21

• TP53mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups, 2019-01-11

• TP53andIDH2somatic mutations are associated with inferior overall survival following allogeneic hematopoietic cell transplantation for myelodysplastic syndrome, 2017-06-16

• Prognostication in Myelodysplastic Syndromes: Beyond the International Prognostic Scoring System (IPSS), 2013-07-01

• Challenges in Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN), 2018-11-23

• Outcome of Patients With Low-Risk and Intermediate-1-Risk Myelodysplastic Syndrome After Hypomethylating Agent Failure A Report on Behalf of the MDS Clinical Research Consortium, 2014-11-19

• A Comprehensive Review of Pacritinib in Myelofibrosis, 2015-09-14

• Lenalidomide Stabilizes the Erythropoietin Receptor by Inhibiting the E3 Ubiquitin Ligase RNF41, 2016-04-06

• Practical Measures of Clinical Benefit With Ruxolitinib Therapy: An Exploratory Analysis COMFORT-I, 2017-05-12

• Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agents, 2015-12-22

• Improved benefit of continuing luspatercept therapy: sub-analysis of patients with lower-risk MDS in the MEDALIST study, 2023-01-13